[Hyperprolactinemic ovarian insufficiency].
About 20% of all menstrual cycle disorders are due to a hyperprolactinemia. Although changes in the bony area of the sella indicating intrasellar space-requiring processes have been found in only 30% of these women presenting hyperprolactinemic ovarian insufficiency, an adenoma of the pituitary gland is probably also responsible for the hyperprolactinemia observed in the rest of the cases. Treatment is however not strictly necessary, as long as there are no other endocrine dysfunctions, and a pregnancy is not desired. Side-effects of a therapy of dopamine agonists can be diminished by a gradually increasing dosage.
D000236:Adenoma / Q000601:surgery; D000568:Amenorrhea / Q000209:etiology; D001971:Bromocriptine / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000628:therapy; D010049:Ovarian Diseases / Q000097:blood* / Q000503:physiopathology / Q000628:therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000517:prevention & control; D011388:Prolactin / Q000097:blood*; D012658:Sella Turcica / Q000000981:diagnostic imaging; D013973:Thyrotropin-Releasing Hormone / Q000502:physiology; D014057:Tomography, X-Ray Computed
D007987:Gonadotropin-Releasing Hormone; D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D004298:Dopamine
Hyperprolaktinämische Ovarialinsuffizienz.